Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.
| Published in: | Targeted Oncology Vol. 18; no. 6; pp. 941 - 953 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
Nov2023
|
| Online Access: | View this record in EBSCOhost |